Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Tocilizumab in Rheumatoid Arthritis
NCT01941095Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2013
- Primary completion
- Jul 2016
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Started Nov 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01941095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01941095.